Results 71 to 80 of about 124,093 (287)

A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.

open access: yes, 2018
BACKGROUND Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure. Phosphodiesterase type 5 inhibitors used for the treatment of erectile dysfunction are also vasodilators, and when taken together
Goggin, Paul   +15 more
core   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr   +15 more
wiley   +1 more source

Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection

open access: yes, 2012
Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as ...
Das, Anindita   +2 more
core   +1 more source

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver [PDF]

open access: yes, 2009
Background The NO - cGMP system plays a key role in the regulation of sinusoidal tonus and liver blood flow with phosphodiesterase-5 (PDE-5) terminating the dilatory action of cGMP.
Deibert Peter   +20 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION

open access: yesЕвразийский Кардиологический Журнал, 2015
The key component of the pathogenesis of pulmonary hypertension (PH) is endothelial dysfunction with imbalance between vasodilators and vasoconstrictors and activation of the blood coagulation system.
T. V. Martynyuk   +5 more
doaj   +1 more source

Development of a Zebrafish Embryo‐Based Test System for Thyroid Hormone System Disruption: 3Rs in Ecotoxicological Research

open access: yesEnvironmental Toxicology and Chemistry, EarlyView.
Abstract There is increasing concern regarding pollutants disrupting the vertebrate thyroid hormone (TH) system, which is crucial for development. Thus, identification of TH system–disrupting chemicals (THSDCs) is an important requirement in the Organisation for Economic Co‐operation and Development (OECD) testing framework.
Lisa Gölz   +9 more
wiley   +1 more source

Malaria parasite cGMP-dependent protein kinase regulates blood stage merozoite secretory organelle discharge and egress. [PDF]

open access: yes, 2013
The malaria parasite replicates within an intraerythrocytic parasitophorous vacuole (PV). Eventually, in a tightly regulated process called egress, proteins of the PV and intracellular merozoite surface are modified by an essential parasite serine ...
Baker, David A   +30 more
core   +1 more source

Obesity and Erectile Dysfunction: From Bench to Clinical Implication

open access: yesThe World Journal of Men's Health, 2019
Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both condi-tions may share an internal pathologic environment, also known as common soil.
Ki Hak Moon   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy